SciSparc Ltd. SPRC
SciSparc Ltd. (Nasdaq: SPRC) is a CNS/neurology/psychiatry drug developer. Its lead program, SCI-110 (THC + PEA/CannAmide), is in Phase 2 for Tourette syndrome; Alzheimer's disease agitation.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SCI-110 | Tourette syndrome (Phase IIa completed; Phase IIb approved in Germany/Israel and FDA IND cleared Oct 2024, not started) | small molecule | Phase 2 |
| SCI-110 | Alzheimer's disease agitation (Phase IIa open-label completed, topline June 2023) | small molecule | Phase 2 |
| SCI-210 (CBD + PEA/CannAmide) | autism spectrum disorder; status epilepticus | small molecule | Pre-clinical |
Recent results and decisions
- Oct 23, 2026started NeuroThera completed manufacturing and obtained batch release certification enabling patient enrollment in Phase IIb trial of SCI-110 for Tourette Syndrome.
The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS.
Filing - Oct 22, 2026started NeuroThera Labs completed manufacturing and obtained European QP batch release certification for SCI-110 Phase IIb trial in Tourette Syndrome, with all three sites activated and ready to receive drug supplies.
Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera, which is now advancing toward patient enrollment in its Phase IIb clinical trial
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.